External broker reports(aggregated public sources), CCZ Statton Equities

CCZ Statton Equities

CCZ is a leading Australian stockbroking firm providing stockbroking and wealth generation services to private clients and institutional investors. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>Eli Lilly has reported positive results from its Donanemab confirmatory phase 3 study, meeting both primary and secondary endpoints.</li><li>In a trial involving 1,736 participants with early Alzheimer's disease, the drug demonstrated a 35% reduction in clinical cognitive decline compared to a placebo.</li><li>The company is on track to complete its submission to the FDA this quarter.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Eli Lilly has reported positive results from its Donanemab confirmatory phase 3 study, meeting both primary and secondary endpoints.In a trial involving 1,736 participants with early Alzheimer's disease, the drug demonstrated a 35% reduction in clinical cognitive decline compared to a placebo.The company is on track to complete its submission to the FDA this quarter.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Cogstate - Donanemab Strikes Second ‘home Run’ for AD Drug Development

Cogstate Ltd

Cogstate - Donanemab Strikes Second ‘home Run’ for AD Drug Development